Biochemical and biophysical approaches to improving the anticancer effectiveness of Ara-adenine.
Ara-C at very low dosage has been reported to decrease the host toxicity of ara-AMP or ara-A in combination with 2'-deoxycoformycin, a potent adenosine deaminase inhibitor, while increasing the toxicity to intracerebral L1210 leukemia. The possibility of increasing the selectivity of ara-A by prior administration of ara-C is explored. The importance of deoxynucleoside kinases, some of which may be cancer-induced, in obtaining selective anticancer effects is discussed. The possibility of a conformational basis for the differing degrees of selectivity and activity of various novel arabinosyl nucleosides is evaluated. The levels of cyclic nucleotides, which have opposing effects on leukemia, may possibly be manipulated to interfere with the growth of cancer cells. Approaches to minimizing major metabolic distortions, such as the progressive accumulation of dATP associated with the use of potent adenosine deaminase inhibitors and which limit the therapeutic effects of ara-A, are proposed.
D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003561:Cytarabine / Q000494:pharmacology; D003838:Deoxyadenine Nucleotides / Q000378:metabolism; D003842:Deoxycytidine Kinase / Q000032:analysis; D006710:Homocysteine / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000032:analysis; D009369:Neoplasms / Q000201:enzymology / Q000378:metabolism; D009712:Nucleotides, Cyclic / Q000032:analysis; D010770:Phosphotransferases / Q000032:analysis; D017853:Phosphotransferases (Alcohol Group Acceptor); D011487:Protein Conformation; D014740:Vidarabine / Q000494:pharmacology* / Q000633:toxicity
D058892:Adenosine Deaminase Inhibitors; D000970:Antineoplastic Agents; D003838:Deoxyadenine Nucleotides; D007527:Isoenzymes; D009712:Nucleotides, Cyclic; D003561:Cytarabine; D006710:Homocysteine; D010770:Phosphotransferases; D017853:Phosphotransferases (Alcohol Group Acceptor); D003842:Deoxycytidine Kinase; C020005:deoxyadenosine kinase; D014740:Vidarabine; C026600:2'-deoxyadenosine triphosphate